Product Details
MW: | 25.4 kDa |
|
Source: | Produced in yeast. Recombinant human granzyme B (aa 21-247). |
|
UniProt ID: | P10144 |
|
Concentration: | 100 U/µl |
|
Formulation: | Liquid. In 50mM TRIS, pH 7.4, 100mM NaCl, 10% glycerol. |
|
Purity Detail: | Partially purified by single-step affinity chromatography and gel filtration. |
|
Biological Activity: | A serine protease with caspase-like substrate specificity. |
|
Specific Activity: | One unit hydrolyzes 1 pmol/min of Ac-IEPD-pNA (200 µM, Prod. No. BML-P133) at 30°C. |
|
Shipping: | Dry Ice |
|
Long Term Storage: | -80°C |
|
Scientific Background: | Granzyme B is a component of the cytolytic granules of cytotoxic T lymphocytes and natural killer cells. |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells: S.R. Woo, et al.; Biochem. Biophys. Res. Commun.
503, 1812 (2018),
Abstract;
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies: I. Albrecht, et al.; J. Clin. Invest.
125, 4612 (2015),
Application(s): Skeletal muscle cell culture,
Abstract;
Full Text
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers: L. Mezache, et al.; Mod. Pathol.
28, 1594 (2015),
Application(s): Immunohistochemistry,
Abstract;
Measurement of Cellular Immunity to Influenza Vaccination in Rheumatoid Arthritis; Comparison of Three Assays: N. Madar-Balakirski, et al.; J. Vaccines Vaccin.
6, 1000278 (2015),
Application(s): Activity Assay,
Full Text
Approaches to design non-covalent inhibitors for human granzyme B (hGrB): M. Kim, et al.; Org. Biomol. Chem.
12, 8952 (2014),
Abstract;
Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis: W.F. Pendergraft, et al.; Kidney Int.
65, 75 (2004),
Abstract;
Related Products